Shoulder Innovations (SI) Competitors

Shoulder Innovations logo
$20.49 -0.20 (-0.98%)
Closing price 03:59 PM Eastern
Extended Trading
$20.49 +0.00 (+0.01%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SI vs. COIN, NVCR, CNMD, TNDM, and STAA

Should you buy Shoulder Innovations stock or one of its competitors? Shoulder Innovations's main competitors and comparable companies include Coinbase Global (COIN), NovoCure (NVCR), CONMED (CNMD), Tandem Diabetes Care (TNDM), and STAAR Surgical (STAA). Companies are selected based on similarities in market, industry, and size.

How does Shoulder Innovations compare to Coinbase Global?

Coinbase Global (NASDAQ:COIN) and Shoulder Innovations (NYSE:SI) are related companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Coinbase Global has higher revenue and earnings than Shoulder Innovations. Coinbase Global is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coinbase Global$7.18B4.71$1.26B-$2.83N/A
Shoulder Innovations$47.32M9.14-$40.36M-$1.62N/A

Coinbase Global has a net margin of -12.46% compared to Shoulder Innovations' net margin of -51.72%. Coinbase Global's return on equity of 0.76% beat Shoulder Innovations' return on equity.

Company Net Margins Return on Equity Return on Assets
Coinbase Global-12.46% 0.76% 0.37%
Shoulder Innovations -51.72%-25.37%-20.87%

In the previous week, Coinbase Global had 41 more articles in the media than Shoulder Innovations. MarketBeat recorded 44 mentions for Coinbase Global and 3 mentions for Shoulder Innovations. Coinbase Global's average media sentiment score of 0.79 beat Shoulder Innovations' score of 0.28 indicating that Coinbase Global is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coinbase Global
21 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
6 Negative mention(s)
3 Very Negative mention(s)
Positive
Shoulder Innovations
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

68.8% of Coinbase Global shares are owned by institutional investors. 16.7% of Coinbase Global shares are owned by insiders. Comparatively, 29.0% of Shoulder Innovations shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Coinbase Global has a beta of 3.35, indicating that its share price is 235% more volatile than the broader market. Comparatively, Shoulder Innovations has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

Coinbase Global presently has a consensus price target of $207.92, suggesting a potential upside of 62.89%. Shoulder Innovations has a consensus price target of $25.75, suggesting a potential upside of 24.58%. Given Coinbase Global's higher possible upside, equities analysts clearly believe Coinbase Global is more favorable than Shoulder Innovations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coinbase Global
4 Sell rating(s)
12 Hold rating(s)
21 Buy rating(s)
0 Strong Buy rating(s)
2.46
Shoulder Innovations
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Coinbase Global beats Shoulder Innovations on 11 of the 16 factors compared between the two stocks.

How does Shoulder Innovations compare to NovoCure?

Shoulder Innovations (NYSE:SI) and NovoCure (NASDAQ:NVCR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

84.6% of NovoCure shares are held by institutional investors. 29.0% of Shoulder Innovations shares are held by insiders. Comparatively, 6.6% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NovoCure has a net margin of -16.78% compared to Shoulder Innovations' net margin of -51.72%. Shoulder Innovations' return on equity of -25.37% beat NovoCure's return on equity.

Company Net Margins Return on Equity Return on Assets
Shoulder Innovations-51.72% -25.37% -20.87%
NovoCure -16.78%-35.81%-15.14%

Shoulder Innovations presently has a consensus price target of $25.75, indicating a potential upside of 24.58%. NovoCure has a consensus price target of $22.33, indicating a potential upside of 88.79%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than Shoulder Innovations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shoulder Innovations
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
NovoCure
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, NovoCure had 14 more articles in the media than Shoulder Innovations. MarketBeat recorded 17 mentions for NovoCure and 3 mentions for Shoulder Innovations. Shoulder Innovations' average media sentiment score of 0.28 beat NovoCure's score of -0.11 indicating that Shoulder Innovations is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Shoulder Innovations
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
NovoCure
1 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
4 Negative mention(s)
2 Very Negative mention(s)
Neutral

Shoulder Innovations has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market. Comparatively, NovoCure has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Shoulder Innovations has higher earnings, but lower revenue than NovoCure. Shoulder Innovations is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shoulder Innovations$47.32M9.14-$40.36M-$1.62N/A
NovoCure$655.35M2.11-$136.23M-$1.06N/A

Summary

NovoCure beats Shoulder Innovations on 9 of the 16 factors compared between the two stocks.

How does Shoulder Innovations compare to CONMED?

CONMED (NYSE:CNMD) and Shoulder Innovations (NYSE:SI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

CONMED has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Shoulder Innovations has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

CONMED presently has a consensus target price of $44.00, indicating a potential downside of 13.10%. Shoulder Innovations has a consensus target price of $25.75, indicating a potential upside of 24.58%. Given Shoulder Innovations' stronger consensus rating and higher possible upside, analysts clearly believe Shoulder Innovations is more favorable than CONMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED
1 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.88
Shoulder Innovations
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

CONMED has a net margin of 5.36% compared to Shoulder Innovations' net margin of -51.72%. CONMED's return on equity of 13.93% beat Shoulder Innovations' return on equity.

Company Net Margins Return on Equity Return on Assets
CONMED5.36% 13.93% 6.26%
Shoulder Innovations -51.72%-25.37%-20.87%

In the previous week, Shoulder Innovations had 3 more articles in the media than CONMED. MarketBeat recorded 3 mentions for Shoulder Innovations and 0 mentions for CONMED. CONMED's average media sentiment score of 1.00 beat Shoulder Innovations' score of 0.28 indicating that CONMED is being referred to more favorably in the media.

Company Overall Sentiment
CONMED Positive
Shoulder Innovations Neutral

CONMED has higher revenue and earnings than Shoulder Innovations. Shoulder Innovations is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$1.37B1.10$47.06M$2.4220.92
Shoulder Innovations$47.32M9.14-$40.36M-$1.62N/A

Summary

CONMED beats Shoulder Innovations on 9 of the 14 factors compared between the two stocks.

How does Shoulder Innovations compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Shoulder Innovations (NYSE:SI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Shoulder Innovations has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.38-$204.71M-$0.72N/A
Shoulder Innovations$47.32M9.14-$40.36M-$1.62N/A

Tandem Diabetes Care currently has a consensus price target of $27.18, suggesting a potential upside of 35.45%. Shoulder Innovations has a consensus price target of $25.75, suggesting a potential upside of 24.58%. Given Tandem Diabetes Care's higher probable upside, equities analysts plainly believe Tandem Diabetes Care is more favorable than Shoulder Innovations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.43
Shoulder Innovations
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Tandem Diabetes Care has a net margin of -4.58% compared to Shoulder Innovations' net margin of -51.72%. Shoulder Innovations' return on equity of -25.37% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-4.58% -35.61% -4.53%
Shoulder Innovations -51.72%-25.37%-20.87%

In the previous week, Tandem Diabetes Care had 18 more articles in the media than Shoulder Innovations. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 3 mentions for Shoulder Innovations. Tandem Diabetes Care's average media sentiment score of 1.05 beat Shoulder Innovations' score of 0.28 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
11 Very Positive mention(s)
7 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Shoulder Innovations
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tandem Diabetes Care has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Shoulder Innovations has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market.

Summary

Tandem Diabetes Care beats Shoulder Innovations on 10 of the 15 factors compared between the two stocks.

How does Shoulder Innovations compare to STAAR Surgical?

Shoulder Innovations (NYSE:SI) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Shoulder Innovations has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

STAAR Surgical has a net margin of 0.16% compared to Shoulder Innovations' net margin of -51.72%. STAAR Surgical's return on equity of 8.43% beat Shoulder Innovations' return on equity.

Company Net Margins Return on Equity Return on Assets
Shoulder Innovations-51.72% -25.37% -20.87%
STAAR Surgical 0.16%8.43%6.50%

96.7% of STAAR Surgical shares are held by institutional investors. 29.0% of Shoulder Innovations shares are held by insiders. Comparatively, 39.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, STAAR Surgical had 1 more articles in the media than Shoulder Innovations. MarketBeat recorded 4 mentions for STAAR Surgical and 3 mentions for Shoulder Innovations. STAAR Surgical's average media sentiment score of 1.03 beat Shoulder Innovations' score of 0.28 indicating that STAAR Surgical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Shoulder Innovations
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
STAAR Surgical
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Shoulder Innovations has higher earnings, but lower revenue than STAAR Surgical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shoulder Innovations$47.32M9.14-$40.36M-$1.62N/A
STAAR Surgical$328.27M4.04-$80.45MN/AN/A

Shoulder Innovations presently has a consensus target price of $25.75, suggesting a potential upside of 24.58%. STAAR Surgical has a consensus target price of $29.00, suggesting a potential upside of 9.89%. Given Shoulder Innovations' stronger consensus rating and higher possible upside, analysts plainly believe Shoulder Innovations is more favorable than STAAR Surgical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shoulder Innovations
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
STAAR Surgical
3 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.23

Summary

STAAR Surgical beats Shoulder Innovations on 10 of the 16 factors compared between the two stocks.

Get Shoulder Innovations News Delivered to You Automatically

Sign up to receive the latest news and ratings for SI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SI vs. The Competition

MetricShoulder InnovationsHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$441.05M$5.95B$7.85B$23.49B
Dividend YieldN/A1.69%2.46%3.78%
P/E RatioN/A35.6832.9124.81
Price / Sales9.065.448.593.24
Price / CashN/A23.9521.9315.51
Price / Book3.624.374.403.66
Net Income-$40.36M$143.12M$3.52B$1.08B
7 Day Performance-4.42%-4.86%-5.34%-3.09%
1 Month Performance13.19%-2.87%-3.61%-1.21%
1 Year Performance39.28%-0.76%0.01%5.63%

Shoulder Innovations Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SI
Shoulder Innovations
2.4455 of 5 stars
$20.49
-1.0%
$25.75
+25.7%
+40.5%$441.05M$47.32MN/A75
COIN
Coinbase Global
3.8461 of 5 stars
$134.76
-1.5%
$209.88
+55.7%
-55.1%$36.36B$7.18BN/A4,951
NVCR
NovoCure
2.0064 of 5 stars
$13.28
-2.0%
$20.80
+56.6%
+4.5%$1.54B$655.35MN/A1,605
CNMD
CONMED
1.5177 of 5 stars
$51.44
-2.6%
$44.00
-14.5%
+20.5%$1.39B$1.37B21.263,900
TNDM
Tandem Diabetes Care
2.9575 of 5 stars
$16.91
-6.0%
$27.18
+60.8%
+7.8%$1.30B$1.01BN/A2,500

Related Companies and Tools


This page (NYSE:SI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners